At ADA 2025, Dr. Mark Atkinson (University of Florida Diabetes Institute) highlighted the systemic benefits of obesity-targeted therapies, including cardiometabolic and cognitive improvements, while noting concerns about implementation and potential muscle loss. Emerging advances in stem cell–derived islet transplantation for type 1 diabetes show promise in reducing insulin dependence. Dr. John Buse (University of North Carolina) presented SOUL trial data indicating that oral GLP-1 receptor agonist therapy reduced major adverse cardiovascular events—CV death, nonfatal MI, or stroke—by 14%, with additional reductions in limb complications in high-risk patients with type 2 diabetes.
Stress echocardiography in heart failure patients: additive value and caveats - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39060836/
Heart failure (HF) is a clinical syndrome characterized by well-defined signs and symptoms due to structural and/or myocardial functional impairment, resulting in raised intracardiac pressures and/or inadequate cardiac stroke volume...
Stress echocardiography is a valuable tool in diagnosing and managing heart failure, revealing subclinical impairments and aiding in risk assessment, particularly for valvular, ischemic, and non-ischemic cardiac conditions.

Patient background: Mr. A, 58, was hospitalized for acute heart failure with reduced ejection fraction (HFrEF), showing a left ventricular ejection fraction (LVEF) of 24%. At discharge, his N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels remained elevated.
Family history: His father had cardiovascular disease and died of heart failure in his 70s.
Assessment and diagnosis: Though guideline-directed medical therapy (GDMT) was initiated at discharge, target doses were rarely achieved. The early post-discharge phase is highly vulnerable and linked to increased morbidity and mortality.
Suggested treatment plan: Recognizing the risks of the post-discharge period, a six-week rapid up-titration program (RTP) was recommended. This approach aimed to optimize all four pillars of GDMT—renin-angiotensin system inhibitors (RASi), β-blockers, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter 2 (SGLT2) inhibitors—in alignment with the 2023 European Society of Cardiology (ESC) heart failure guidelines.
Patient education: Mr. A was counseled on the proven benefits of comprehensive GDMT and the safety of RTP when paired with close monitoring. Emphasis was placed on adherence to therapy and regular follow-up.
Follow-up: The RTP involved six structured visits (in-hospital and remote). Clinical markers—including systolic blood pressure (SBP), heart rate (HR), renal function, potassium, and NT-proBNP—were monitored weekly. LVEF re-evaluation was scheduled 2–4 months post-RTP.
- Why is rapid GDMT up-titration crucial immediately post-discharge for heart failure patients? Answer The early post-discharge phase is high risk. Rapid GDMT titration reduces mortality and rehospitalization by addressing this vulnerable period with evidence-based care.
- How are safety indicators managed during RTP to ensure optimal GDMT implementation? Answer Safety parameters (eg, SBP, HR, estimated glomerular filtration rate [eGFR], potassium) are closely monitored. Most patients can achieve target GDMT doses safely with proper adjustments and follow-up.
Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40162940/
The triad of obesity, HFpEF, and CKD identifies patients with considerable functional impairment and an unfavorable prognosis, who nevertheless respond favorably to tirzepatide. Long-term tirzepatide improves renal function (both by...
In obese HFpEF patients, tirzepatide improved heart failure outcomes and renal function regardless of CKD status, though eGFR assessments varied by biomarker due to body composition effects on creatinine and cystatin C.
